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Lung cancer is the leading cause of cancer deaths in the United States, accounting 
for 27% of all cancer induced deaths
1
.  In an attempt to create a effective targeted therapy 





transgenic lung cancer mouse model was to deliver a known tumor suppressive 
microRNA (miRNA) to stop tumor growth.  The tumor suppressive miRNA let-7 was 
lentivirally delivered in the form of its primary transcript, pri-let-7a-1, and resulted in 
increased lung size and inflammation compared to lungs exposed to a control lentivirus.  
It was identified that LIN28B transcripts were elevated in this transgenic model
2
 and a 
truncated MYC protein product, separate from canonical MYC, was overexpressed with 
activation of the transgenic lung cancer mouse model.  LIN28B is a pluripotent factor and 
post-transcriptional inhibitor of let-7 biogenesis
3–5
. Therefore, it was hypothesized that 
the LIN28B mediated accumulation of pri-let-7a-1 transcripts promoted expression of the 
truncated MYC protein product, termed T-MYC.  Through this work, it was determined 
that T-MYC expression is not dependent on the LIN28B mediated accumulation of pri-









Lung cancer is the largest contributor to the total number of cancer deaths 
worldwide with an estimated 158,040 deaths in the United States in 2015; 26.8% of all 
cancer associated deaths.  Additionally, the number of new lung cancer diagnoses 
increases every year with an estimated 221,200 new cases in 2015 alone
1
.  Despite efforts 
to create effective therapies for the treatment of lung cancer, the five-year survival rate 
for patients with this cancer type remains at a dismal 17%
1
.  This poses a great challenge 
to both the medical and scientific communities to elucidate the underlying causes of lung 
cancer.   
 Patients who are diagnosed with lung cancer are typically recommended to 
undergo initial treatments that are more general in nature.  This often includes measures 
such as the surgical removal of tumor tissue from the lungs in early stages of disease 
progression and chemotherapy or radiation therapy
6
.  A major limitation in utilizing these 
techniques as a means of treating the disease is that lung cancer is typically not detected 
until later stages of progression, a point in time when metastatic disease is much more 
likely.  This creates a situation in which traditional treatment measures, i.e. surgery, 
chemotherapy, and radiation therapy, are much less effective in halting lung cancer 
growth and progression
7





 effort has been expended on developing therapies that are specific and more effective in 
treating late-stage lung cancer, a more aggressive disease state. 
 Lung cancer, when diagnosed, is categorized into one of several subtypes 




, and lung carcinoid 
tumors
10
 are the subgroups that are used clinically to classify lung cancers.   Non-small 
cell lung cancer (NSCLC) is the most prevalent type, comprising approximately 80% of 
diagnosed lung cancers.  This lung cancer subtype encompasses several types of cancers, 
including squamous cell carcinoma, large cell carcinoma, and adenocarcinoma
11
.   
 It is well known that the molecular landscape within a cancer cell is dysregulated 
when compared to its normal, healthy counterpart; that is, many normal cellular processes 
and molecular mechanisms are altered in cancer and much of this alteration has been 
established as being crucial for the development, maintenance, and growth of cancer.  In 
cancer, this often results in the up- or down-regulation of factors that are important for 
development as well as maintaining a differentiated cellular state.  Factors that are down 
regulated in cancer and are important for limiting cellular growth and promoting 
processes that result in cellular death are called tumor suppressors.  Vice-versa, 
oncogenic factors are up regulated in cancer and allow cells to overcome processes that 
are important in controlling how cells grow and eventually die
12
.  Efforts to create a 
targeted therapy for cancer are often focused on either the reintroduction of tumor-
suppressive factors in a background where they are lost or blocking the action of 
oncogenic factors that are up regulated in a cancer type.   
 The major drugs currently on the market for the targeted treatment of late stage 





Gefitinib and erlotinib are small molecule inhibitors that specifically target and block the 
action of the epidermal growth factor receptor, EGFR
13
.  EGFR is a gene that has been 
found to be mutated and upregulated in approximately 43-89% of NSCLC tumors
14
 and 
is responsible for activating signaling that promotes cell growth
14
.  While it has been 
demonstrated that these drugs are effective in inhibiting the action of EGFR, their 
effectiveness is limited to lung cancers with EGFR upregulation.  There are additional 
targeted therapies for the treatment of lung cancer, but they also rely on the upregulation 
of specific oncogenic factors that have implications in promoting lung cancer 
progression
15,16
.  Inhibitors that block the anaplastic lymphoma kinase, ALK, are also 
used for the targeted treatment of lung cancer but are more limited as ALK 
rearrangements implicated in cancer formation are seen in approximately 2-7% of 
NSCLC tumors
15,17,18
.  This poses a significant challenge to researchers to elucidate 
additional mechanisms that are widely activated in lung cancer that could serve as a basis 
of therapeutic intervention.   
MYC is a family of proto-oncogenic transcription factors that have been 
established to be important in development and are also implicated in promoting 
cancer
19–21
.  The increased expression of MYC, through varying mechanisms, is observed 
in approximately 30% of all cancers, signifying its importance and broad impact as an 
oncogene
22,23
.  When expressed, MYC forms a dimer with a protein, MAX, that 
positively regulates the effects of MYC, binds to E-box sequences contained within the 
promoters of genes, and mediates transcriptional changes to its target genes
24,25
.  Studies 
focused on understanding exactly what genes MYC regulates have revealed its ability to 





being actively transcribed within a cell
26,27
.  The response of cells to increased expression 
of MYC include, but are not limited to, changes in processes that promote cancer such as 
inducing cell cycle progression, influencing apoptosis, decreasing genomic stability, and 
enhancing cell growth
28
.  The broad reaching effects of MYC on cells make it not only an 
important oncogene but therapeutically intervening on its action could prove to be an 
invaluable asset in the treatment of many different cancer types, including lung cancer.  
Interestingly, there are several family members of MYC that have varying 
abilities of producing the pro-tumorigenic phenotype associated with MYC’s oncogenic 
function.  Of the family members, only N-MYC, c-MYC, and L-MYC have been 
demonstrated to have the potential to lead to neoplastic growth when expressed in 
cancer
29
.  c-MYC is expressed in many different cancer types, L-MYC is expressed in 
small cell lung cancer
30
, and N-MYC expression is seen in neuroblastoma
31
.  
Additionally, there are protein products that arise from alternative translation of MYC 
mRNA.  These products are collectively called MYC-S and are truncated versions of c-
MYC, lacking the N terminus of the canonical protein product.  It has been demonstrated 
that these products have the ability to form a dimer with Max, the positive regulator of 
MYC, and inhibit transactivation of transcription of canonical MYC targets
32,33
.  
Together, this demonstrates one facet of the complexity surrounding the biology of MYC 
and its family members within the context of cancer. 
In an effort to understand the regulatory mechanisms MYC’s expression 
influences, it was identified that one subset of transcripts that MYC regulates is that of 
microRNAs (miRNAs)
34
.  miRNAs are small, 18-24 nucleotide, non-coding RNAs that 






Figure 1: Canonical microRNA biogenesis pathway. The primary miRNA is 
transcribed by RNA Polymerase II and forms the characteristic hairpin-loop structure. 
The flanking regions of the transcript are cleaved by DROSHA and DGCR8 to form the 
precursor miRNA.  The precursor miRNA is then exported into the cytoplasm where it is 
further cleaved by DICER.  The guide strand is then loaded into Argonaute and further 
associates with the RNA Induced Silencing Complex to mediate mRNA degradation or 














form a hairpin loop structure, as seen in Figure 1
35
.  The pri-miRNA is then processed 
into a shorter transcript, termed the precursor miRNA (pre-miRNA), by the RNAse 
processing enzyme DROSHA.  The pre-miRNA is exported into the cytoplasm where it 
undergoes further cleavage into a double stranded RNA molecule by another RNase 
enzyme, DICER
36
.  The guide strand of the miRNA duplex is then loaded into Argonaute, 
a component of the RNA Induced Silencing Complex (RISC).  RISC is then poised for 
the post-transcriptional down-regulation of gene expression, and ultimately protein 
expression, through base complementarity of the mat-miRNA with its target messenger 
RNAs (mRNAs)
36,37
.  miRNA mediated regulation of genes signifies an important 
regulatory mechanism that contributes to maintaining cellular states in development and 
differentiation and is a mechanism that is highly dysregulated in cancer.   
Accordingly, MYC can both up- and down-regulate the expression of both tumor 
suppressive and oncogenic miRNAs, which can influence the fate of cells.  For example, 
MYC has been shown to directly cause the expression of miR-17-92, an oncogenic 
miRNA cluster, which contributes to the tumorigenic phenotype associated with MYC by 
regulating genes that control chromatin modifications
38
.  Alternatively, MYC also causes 
down-regulation of miRNAs important in controlling a proliferative phenotype, such as 
the tumor suppressive miRNA let-7.  let-7 was originally identified in Caenorhabditis 
elegans as an important developmental regulator and was later found to be conserved in 
humans.  let-7 expression is commonly down-regulated or lost in cancer, allowing for the 
uncontrolled expression of its target proto-oncogenes such as KRAS, MYC, and 
LIN28B
39–42






Figure 2: Negative feedback regulation of MYC, LIN28B, and let-7. In a 
differentiated cell, canonical let-7 processing occurs allowing the negative regulation of 
MYC and LIN28B. In cancer, the expression of MYC promotes LIN28B expression, 











in turn blocks the processing of let-7 due to LIN28B being a post-transcriptional inhibitor 
of let-7 biogenesis.  This signifies an important negative feedback loop where in a 
differentiated cell, let-7 targets and down-regulates both MYC and LIN28B but in a 
neoplastic state, such as cancer, the expression of these oncogenes is uncontrolled
3,39
.  
The overexpression of MYC and subsequently LIN28B then causes the decreased 
maturation of let-7
3
. MYC expression causes large changes in regulatory mechanisms 
that contribute to the tumorigenic state often associated with expression of this oncogene 
in cancers.  Restoring regulatory mechanisms that are dysregulated by MYC not only 
contributes to understanding the role of MYC in cancer, but could also reveal potential 
therapeutic targets for the treatment of cancer.   
Therapies have been developed to directly block the action of MYC within cancer 
which includes strategies to create small molecule inhibitors of MYC-Max dimerization
43
 
as well as targeting upstream mechanisms that influence MYC’s expression and activity
44
.  
Creating effective targeted therapies against transcription factors has proven to be 
difficult due to the fact that they lack enzymatic activity, thus having less specific drug 
targets within their protein structure
45
.  In the past few years, however, the therapeutic 
potential of using miRNAs as an intervention has shown promising results
46–48
.  miRNAs 
as a whole can be classified as either being tumor suppressive or oncogenic.  Tumor 
suppressive miRNAs usually down regulate processes that contribute to cancer and their 
expression is decreased or nonexistent in cancer.  Oncogenic miRNAs are overexpressed 
in cancer and their expression results in a pro-tumorigenic phenotype
46,48
.  Due to the fact 
that a single miRNA has many mRNA targets
37
, the reintroduction of a single tumor 





cocktail through reestablishing the canonical regulation of many genes at once.  This has 
been demonstrated with the miRNA, miR-34, a tumor suppressive miRNA commonly 
down regulated in cancer
49
.  A miR-34 mimic is currently in clinical trials for the 
treatment of cancer due to its demonstrated ability to inhibit cellular processes that 
contribute to tumor formation and growth
50,51
.  There is great potential in exploiting the 
use of miRNAs as a cancer therapy not only to reestablish tumor suppressive mechanisms 
but to also block oncogenic processes occurring within cancer.  miRNA therapies could 
greatly contribute to the treatment of lung cancer, an aggressive cancer type with few 
effective therapeutic options.  
To test the effectiveness in using microRNAs (miRNAs) as a therapeutic 
intervention, it was hypothesized that a tumor suppressive miRNA could be exogenously 





transgenic mouse model.  The transgenes in this model are 
activated through genomic recombination of loxP sites with Cre Recombinase and results 
in production of mutant Kras and p53.  KRAS mutation, and subsequent overexpression, 
has direct implications in lung cancer and is found in approximately 30% of lung 
adenocarcinomas
52
.  TP53 encodes the tumor suppressive protein p53 that is the most 
commonly perturbed gene in cancer, mutated in approximately 40% of all lung cancers
53
.  
To test the hypothesis that a tumor suppressive miRNA could halt tumor growth in this 





 transgenic mouse model.  Primary-let-7a-1 (pri-let-7a-1) is the full 
length transcript of let-7a that requires processing through the canonical miRNA 





its mature transcript, mat-let-7a.  The response seen with the lentiviral delivery of pri-let-
7a-1 was increased lung size and inflammation compared to lungs exposed to a lentiviral 
control, as seen in Figure 3.  This result was in strict contrast to the hypothesis that pri-
let-7a-1 would be processed through the canonical miRNA biogenesis pathway, seen in 
Figure 2, and mat-let-7a and would subsequently downregulate its target oncogenes and 
ultimately halt tumor progression.   




 transgenic model that LIN28B 
transcripts were overexpressed
2
.  LIN28B is a post-transcriptional regulator of let-7 that 
blocks maturation of let-7 sequences, negating the tumor suppressive capabilities of let-
7
4,5,54,55
.  It was hypothesized that let-7 targets would be dysregulated in this model due to 
the LIN28 mediated inhibition of let-7 biogenesis. To determine if let-7a targets were 




 activated transgenic mouse model, lung tissue 
was assessed for the presence of MYC, a known oncogene that is targeted and down-
regulated by mat-let-7a
39,56
.  In tissues of a non-activated (normal) lung compared to 




 activated model of lung tumor formation, 
the expression of canonical MYC was not affected.  Interestingly, however, a truncated 
form of MYC was detected as being overexpressed in the activated tumor model 
compared to the normal lung tissue, seen in Figure 4. This led to the overall hypothesis of 
this work that the LIN28B mediated accumulation of pri-let-7a-1 promoted the 
expression of a truncated form of MYC.  To test this hypothesis, this work is divided into 
two main areas.  First, since it was hypothesized that the truncated MYC protein product 
was indeed a variant of MYC, this protein was characterized.  Secondly, the ability of pri-







                                         
Figure 3: Lentivirally delivered pri-let-7a-1 increases lung size. Pri-let-7a-1 was 




 lung cancer mouse model, lungs were 












       





lung cancer mouse model. Transgenic mice were administered adenovirus-cre and 
tumor formation progressed for 19 weeks.  Protein was extracted and assessed for the 



















 transgenic mouse model causes expression 
of mutated Kras and p53 which leads to tumor formation
2
.  Molecularly, it was identified 
that a truncated variant of canonical MYC, termed T-MYC, was also overexpressed upon 
activation of this lung cancer model.  As a means of determining if T-MYC was indeed a 
truncated variant of canonical MYC, several strategies were implemented to characterize 
this novel protein product.   
The expression of T-MYC was first identified in vivo and was hypothesized to be 
induced by the accumulation of pri-let-7a-1 through LIN28B.  To test that the expression 
of the truncated form of MYC, termed T-MYC, could be replicated in vitro, the lentiviral 
plasmid that expresses the pri-let-7a-1 sequence was transfected into A549 and Calu6 
lung adenocarcinoma cell lines, both which have detectable levels of LIN28B expression.   
After transfection of lenti-pri-let-7a-1 as well as a control lentiviral plasmid, cell lysates 
were assessed for the presence of T-MYC through SDS-PAGE and immunoblotting.  As 
seen in Figure 5, T-MYC expression was induced in both A549 and Calu6 cell lines when 
the lenti-pri-let-7a-1 plasmid was transfected compared to lysates obtained from cells 





           
Figure 5: T-MYC expression is induced in cell culture. A control lentiviral plasmid or 
lenti-pri-let-7a-1 was transfected in A549, A., and Calu6, B., lung adenocarcinoma cells. 
48hrs post-transfection cells were lysed and protein was analyzed for the expression of T-






expression could be duplicated in vitro and signified its potential as a contributor to the 
pro-tumorigenic phenotype seen when lenti-pri-let-7a-1 was transduced in vivo. 
In an effort to further validate T-MYC as an alternate form of canonical MYC, 
several strategies were utilized.  The first strategy was to simply determine if T-MYC 
could be detected through immunoblotting with several different primary antibodies 
generated to bind MYC.  To do so, T-MYC expression was induced by transfection of the 
lenti-pri-let-7a-1 plasmid in A549 cells and compared to cells transfected with a control 
lentiviral plasmid.  Cellular lysates obtained post-transfection were assessed through 
SDS-PAGE and immunoblotting for the presence of T-MYC expression using several 
different primary antibodies that detect human MYC.  Three antibodies were used to 
detect MYC, one that was generated to bind an epitope closer to the N-terminus of MYC 
made by Cell Signaling and two that were generated to recognize and bind closer to the 
C-terminus of MYC made by Sigma Aldrich and Abcam.  Interestingly, T-MYC was 
detected only using antibodies generated to bind epitopes on the C-terminus of MYC, as 
seen in Figure 6.  This finding suggested that T-MYC was a protein variant of canonical 
MYC and that it was lacking most of the N-terminus but retained the C-terminus of 
canonical MYC within its protein structure. 
Small-interfering RNA (siRNA) mediated knock-down of T-MYC was a final 
strategy employed to understand if T-MYC was in fact a protein variant of MYC.  It was 
hypothesized that if T-MYC is a truncated form of canonical MYC, then it would be 
knocked down with an siRNA that also knocks down canonical, full-length MYC.  To 







Figure 6: T-MYC is detected with two antibodies generated to detect the C-terminus 
of MYC.  A549 lung adenocarcinoma cells were transfected with a control lentiviral 
plasmid or lenti-pri-let-7a-1. 48hrs post transfection, cells were lysed and protein 
extracted was assessed for the presence of T-MYC through SDS-PAGE and 
immunoblotting. Antibody 1 (Ab1) was produced by Cell Signaling, Antibody 2 (Ab2) 









let-7a-1 plasmid along with a control, scrambled, siRNA or one of two siRNAs designed 
to target and downregulate MYC.  After transfection, cell lysates were obtained and 
assessed for both canonical MYC and T-MYC expression through SDS-PAGE and 
immunoblotting.  As seen in Figure 7, canonical MYC expression was only 
downregulated when the siRNAs targeting c-MYC was co-transfected, as expected.  On 
the other hand, T-MYC was induced when the lenti-pri-let-7a-1 plasmid was transfected 
into the cells, but its expression was not affected by co-transfection of the siRNA 
targeting the   end of the MYC transcript.  However, T-MYC was knocked down with co-
transfection of the siRNA targeting the   end of the MYC transcript.  This finding 
indicated that a transcript variant of MYC induced by pri-let-7a-1 expression was possibly 
responsible for the expression of T-MYC.   
To further investigate the possibility that a MYC transcript variant was responsible 
for the induction of T-MYC, it was hypothesized that the expression of total MYC 
transcripts would increase with the transfection of lenti-pri-let-7a-1.  To test this 
hypothesis, protein and RNA were extracted after co-transfection of lenti-pri-let-7a-1 
with a scrambled, control siRNA or a siRNA targeting the   end of MYC transcripts and 
compared to transfection with a control lentiviral plasmid in A549 lung adenocarcinoma 
cells.  Protein was extracted from cell lysates and assessed for the expression of canonical 
MYC and T-MYC through SDS-PAGE and immunoblotting.  As seen in Figure 8A, the 
expression of canonical MYC was decreased with co-transfection of the siRNA targeting 
MYC, as expected.  The expression of T-MYC was induced by transfection of lenti-pri-
let-7a-1 and was unchanged by co-transfection of the siRNA targeting the   end of MYC, 






Figure 7: T-MYC is possibly expressed from a transcript variant of the canonical 
MYC transcript. A549 lung adenocarcinoma cells were cotrasfected with lenti-pri-let-
7a-1 and either a control, scrambled siRNA or a siRNA targeting MYC. Lysates were 

















Figure 8: T-MYC is not a transcript or protein variant of canonical MYC. A549 
lung adenocarcinoma cells were co-transfected with a control lentiviral plasmid or lenti-
pri-let-7a-1 and a control siRNA or a siRNA targeting Myc.  48hrs post-transfection 
protein and RNA were extracted. A. Protein was assessed for the expression of T-Myc 
through SDS-PAGE and immunoblotting. B. RNA was reverse transcribed and used in 
qPCR with primers spanning the two exon junctions in MYC, MYC Exon 1/2 and MYC 
Exon 2/3.  Β-Actin was used as the normalizer for gene expression and the control 
plasmid/control siRNA transfection served as the internal control. Error bars were 
generated by calculating the standard deviation of expression values obtained by utilizing 
the comparative Ct method with the control plasmid, control siRNA transfection serving 
as the internal control. Significance was determined through subjecting expression values 





the transfection of lenti-pri-let-7a-1, the RNA also extracted from the cells after 
transfection underwent reverse transcription and was utilized in qPCR to further 
understand if a MYC transcript variant was induced by lenti-pri-let-7a-1.  Two primer sets 
were used in qPCR, one that spanned the junction between exons 1 and 2 in MYC, MYC 
Exon1/2, and one primer pair that spanned the junction between exons 2 and 3 in MYC, 
MYC Exon2/3.  As seen in Figure 8B, the expression of MYC was unchanged when lenti-
pri-let-7a-1 was transfected compared to the lentiviral control transfection.  When lenti-
pri-let-7a-1 was co-transfected with the siRNA targeting MYC, however, the expression 
of MYC decreased.  Since T-MYC expression was observed with transfection of lenti-pri-
let-7a-1 but there was no change in the expression of MYC, the hypothesis that a 
transcript variant was being expressed was false.  Additionally, the co-transfection of 
lenti-pri-let-7a-1 with the siRNA targeting MYC resulted in the decreased expression of 
the MYC protein product as well as MYC transcripts but the expression of T-MYC was 
unchanged.  This indicated that T-MYC is likely not a protein or transcript variant of 
canonical MYC. 
Although the expression of T-MYC was clearly induced by the transfection of 
lenti-pri-let-7a-1 and detected with multiple antibodies that bind MYC, it was determined 
that T-MYC was not a protein or transcript variant of canonical MYC.  The detection of 
T-MYC may be explained simply by conservation of the region that both the antibodies 
recognized.  The c-terminus of MYC contains a basic helix-loop-helix (bHLH) domain, 
which is part of diverse family of transcription factors that also contain this domain
57–59
.  
It is possible that the transfection of lenti-pri-let-7a-1 causes the induction of another 





Regardless, while T-MYC is likely not a variant of canonical MYC the implications of its 







CHAPTER 3: EVALUATING THE ABILITY OF PRI-LET-7A-1 TO INDUCE 









 mouse model and later when a lentiviral plasmid expressing 
primary-let-7a-1 (pri-let-7a-1) was transfected in cell culture.  The induction of T-MYC 
expression was consistently seen in backgrounds where LIN28B was also expressed 
which led to the hypothesis that the accumulation of pri-let-7a-1 through LIN28B 
promoted the expression of T-MYC.  Several strategies were used to understand if T-
MYC expression was dependent upon pri-let-7a-1 and LIN28B. 
Since T-MYC expression was induced with the transfection of the lentiviral 
plasmid that expresses pri-let-7a-1, it was initially hypothesized that pri-let-7a-1 induced 
expression of T-MYC.  Several plasmids were created based on the lenti-pri-let-7a-1 
plasmid to test if T-MYC expression was dependent on pri-let-7a-1.  First, pri-let-7a-1 
was excised from the lentiviral plasmid, lenti-pri-let-7a-1, and named lenti-Δpri-let-7a-1.  
An additional plasmid was created in which pri-let-7a-1 was cloned from lenti-pri-let-7a-
1 into a non-lentiviral expression backbone and named pPNB-1.  These constructs, along 
with a lentiviral plasmid that expresses pri-let-7b, were transfected into H441 and A549 
lung adenocarcinoma cells.  It was hypothesized that only the plasmids that expressed 
pri-let-7a-1 would induce the expression of T-MYC in A549 cells and not H441 since 





seen in Figure 9, T-MYC expression was induced only by the lenti-pri-let-7a-1 and lenti-
Δpri-let-7a-1 in both A549 and H441 lung adenocarcinoma cells.  This result indicated 
that T-MYC expression is not dependent upon pri-let-7a-1 expression or to other let-7 
family members, but is inherent to the lentiviral backbone.  Additionally, since T-MYC 
expression was seen in both A549 and H441 cells, its expression is therefore not 
dependent upon pri-let-7a-1 or LIN28B expression.   
The preliminary data generated in vivo shows that T-MYC expression was 




 model was activated through transduction with 
adenovirus Cre Recombinase, as seen in Figure 2.  This in combination with the finding 
that the lentiviral backbone was responsible for inducing expression of T-MYC, Figure 6, 
led to the hypothesis that T-MYC expression may be conserved and inherent to 
transduction with viral particles.  To test this, A549 cells were transduced with lentivirus 
and adenovirus and their cell lysates were probed for T-MYC through SDS-PAGE and 
immunoblotting.  As seen in Figure 10, T-MYC was induced with transfection of the 
positive control, lenti-pri-let-7a-1, but not when transduced with lentivirus or adenovirus.  
These findings indicate that T-MYC expression is not induced by transduction of cells 
with lentivirus and adenovirus.  The induced expression of T-MYC is inherent to the 
original lentiviral backbone that was used to overexpress genes of interest. 
One caveat of this study that was identified was the fact that T-MYC expression is 
only induced in cell culture by transfection of lenti-pri-let-7a-1 and that transfection of 
the lentiviral control plasmid did not promote expression of T-MYC.  In the original 
study determining the effectiveness of the lentiviral delivery of pri-let-7a-1, the original 






Figure 9: T-MYC expression is independent of pri-let-7a-1.  H441, A., and A549, B., 
lung adenocarcinoma cells were transfected with plasmids that expressed (lenti-pri-let-
7a-1, pPNB-1) and did not express pri-let-7a-1 (Lenti-control, lenti-Δpri-let-7a-1 and 
lenti-let-7b).  48hrs post transfection, cells were lysed and protein was assessed for the 

















Figure 10: T-MYC expression is not induced by viral transduction in cell culture. 
H441 lung adenocarcinoma cells were transfected with a control lentiviral plasmid or 
lenti-pri-let-7a-1, or were transduced with lentivirus or adenovirus.  48hrs post 
transfection cells were lysed and protein was extracted and assessed for T-MYC and β-














Biosciences.  When trying to propagate and transfect the lentiviral control, the plasmid 
was difficult to prepare at working concentrations and failed when used to try to create 
lentivirus for transduction in vivo.  Thus, an updated lentiviral control was obtained from 
System Biosciences while pri-let-7a-1 was still used in the older plasmid system.  This 
indicates that T-MYC expression is somehow only inherent to the older lentiviral plasmid 
system by System Biosciences and T-MYC expression is not induced by the updated 
lentiviral system. 
It was hypothesized that the accumulation of pri-let-7a-1 through LIN28B 
expression induced the expression of T-MYC.  However, it was determined that T-MYC 
expression is not dependent upon the expression pri-let-7a-1 or LIN28B.  The expression 
of T-MYC is promoted simply by the transfection of the lentiviral plasmid void of pri-let-
7a-1, indicating that T-MYC expression inherent to a component of the older lentiviral 


















The treatment of lung cancer is currently an area that represents a great deal of 
research effort both in academia and industry due to the fact that lung cancer is currently 
responsible for more cancer deaths per year than any other cancer type.  In the United 
States in 2015, it was estimated that there would be 158,040 lung cancer deaths with an 
additional 221,200 new diagnoses
1
.  Those who are diagnosed with lung cancer are faced 
with a 17% 5-year survival rate mainly due to most lung cancer cases not being detected 
until later stages of cancer progression
1
.  A later diagnosis indicates a point in time when 
metastasis is much more likely, meaning a less treatable and much more aggressive time 
in disease progression.  Creating effective targeted therapies for the treatment of lung 
could greatly increase the 5-year survival rate of lung cancer patients and decrease the 
number of lung cancer associated deaths in the United States and globally.   
One strategy for the targeted treatment of lung cancer that has shown promising 
results is the use of microRNAs (miRNAs) as a therapeutic intervention.  miRNAs are 
transcribed from the genome into a long, primary microRNA (pri-miRNA) and undergo 
further processing in the nucleus and cytoplasm, respectively, to form a shorter 18-24 
nucleotide mature microRNA (mat-miRNA) duplex.  The guide strand of the duplex then 





complementarity with messenger RNAs (mRNAs), mediates the post transcriptional 
down-regulation of protein expression through mRNA degradation or blocking 
translation of mRNA targets
37
.  Tumor suppressive miRNAs typically have decreased 
expression in cancer compared to normal, healthy tissue and function by targeting and 
regulating the expression of factors that promote tumorigenic processes.  Oncogenic 
miRNAs have increased expression in cancer compared to normal tissues and target 
factors that are important in promoting anti-tumorigenic effects
46,48
.  Therefore, the 
reintroduction of a tumor suppressive miRNA into a background where its expression is 
lost or blocking the action of an oncogenic miRNA could restore the regulation of many 
genes at one since one miRNA has many mRNA targets
37
.   
let-7 is a tumor suppressive miRNA that has been observed to have decreased 
expression in many cancer types
60,61
.  The ability of a let-7 mimic to decrease the 
tumorigenic phenotype seen in cancer has also been demonstrated in vivo
61
.  These 
findings led to the hypothesis that the exogenous delivery of let-7 would be advantageous 





 transgenic mouse model that is activated by the recombination of 
loxP sites with exposure to adenovirus-cre recombinase.  Activation of this model results 
in the constitutive expression of a mutated form of Kras, a known oncogene
52,62
, and 
mutation of the tumor suppressive factor p53
53
. To test the hypothesis that let-7 could be 
exogenously delivered to this model and stop tumor growth and progression, primary-let-





transgenic mouse model.  Primary-let-7a-1 (pri-let-7a-1) is the unprocessed transcript of 





7a, and mediate its proven tumor suppressive capabilities
37
.  The effect seen with the 
lentiviral transduction of pri-let-7a-1 was increased lung size and inflammation compared 
to lungs exposed to a control lentivirus.  This result went against the hypothesis that pri-
let-7a-1 would be processed into mat-let-7a, target oncogenes and mediate a decrease in 




 mouse model.   




 activated mouse model, 
that LIN28B transcripts were elevated
2
.  LIN28B is a pluripotent factor that is 
overexpressed in some cancers and mediates part of its pro-tumorigenic capabilities 
through the post-transcriptional inhibition of let-7 biogenesis
3–5
.  Since LIN28B inhibits 
the tumor suppressive capabilities of let-7, it was hypothesized that let-7 targets would be 




 mouse model.  One target of let-7 
is that of MYC, a well known oncogene that is overexpressed in approximately 30% of 
all cancers
22,23





 activated model compared to lungs harvested from non-
tumorigenic mice.  The expression of canonical MYC was not affected by activation of 





 activated model compared to non-tumorigenic lung tissue, seen in 
Figure 4.  This led to the hypothesis that increased LIN28B expression causes the 
accumulation of pri-let-7a-1 transcripts, which promotes the expression of the truncated 
MYC protein product, termed T-MYC.   
 To understand if T-MYC was indeed a truncated form of canonical MYC, several 
strategies were employed.  The induction of T-MYC was proven to be reproducible in 









 model.  This finding confirmed that T-
MYC expression could be replicated both in vitro and in vivo.  T-MYC was also only 
detected with multiple primary antibodies generated to detect the C-terminus of MYC in 
SDS-PAGE and immunoblotting, seen in Figure 6, but not with an antibody that binds to 
an epitope on the N-terminus of MYC.  This result led to the hypothesis that T-MYC is a 
truncated form of canonical MYC that retains only the C-terminus of MYC but does not 
contain the N-terminus of MYC within its protein structure.  In an attempt to further 
characterize T-MYC, small-interfering RNA (siRNA) mediated knock-down was 
employed with the hypothesis that if T-MYC is a protein variant of MYC, it would be 
knocked down when co-transfected with a siRNA targeting MYC in A549 cells.  As seen 
in Figure 7, canonical MYC was  noc ed do n  it  si   s targeting  ot  t e   and   
end of the MYC transcript, determined through SDS-PAGE and immunoblotting.  
However, T-MYC was only knocked down with the siRNA designed to target the   end 
of MYC.  This led to the hypothesis that a transcript variant separate from the canonical 
MYC transcript was being expressed with the transfection of the plasmid that promoted 
the expression of T-MYC, lenti-pri-let-7a-1.  To understand if a T-MYC transcript variant 
was induced upon expression of T-MYC, A549 cells were co-transfected with lenti-pri-
let-7a-1 and a control scrambled siRNA sequence or a siRNA targeting the   end of MYC.  
As seen in Figure 8, the expression of canonical MYC was unchanged by the transfection 
of lenti-pri-let-7a-1 and a control siRNA but decreased when lenti-pri-let-7a-1 was co-
transfected with the siRNA targeting MYC, as expected.  Through using qPCR, it was 
found that the expression of MYC transcripts was unchanged when T-MYC was induced 





T-MYC expression remained unchanged.  Since the total expression of MYC did not 
change when T-MYC was induced, it was concluded that T-MYC was not expressed 
from a transcript variant of canonical MYC.  Additionally, since MYC expression 
decreased both at the transcript and protein levels when cells were transfected with the 
siRNA targeting MYC, it was concluded that T-MYC is also likely not a protein variant 
of MYC. 





 transgenic mouse model that has increased LIN28B transcript 
levels
2
.  T-MYC expression was also seen through transfection of the lentiviral plasmid 
that overexpresses pri-let-7a-1, lenti-pri-let-7a-1, in cells that had detectable levels of 
LIN28B expression, A549 and Calu6.  Since T-MYC expression was observed in 
backgrounds with detectable LIN28B expression, it was hypothesized that the LIN28B 
mediated accumulation of pri-let-7a-1 transcripts induced the expression of T-MYC.  To 
test this hypothesis, several plasmids based off of lenti-pri-let-7a-1 were created.  The 
pri-let-7a-1 sequence was removed from the lenti-pri-let-7a-1 plasmid, termed lenti-Δpri-
let-7a-1, and was also cloned into a non-lentiviral backbone, termed pPNB-1.  These 
constructs, along with a lentiviral plasmid that overexpressed pri-let-7b, were transfected 
in H441 and A549 lung adenocarcinoma cell lines.  As seen in Figure 9, only the 
plasmids that were based on the original lentiviral construct, lenti-pri-let-7a-1 and lenti-
Δpri-let-7a-1, promoted the expression of T-MYC.  This finding indicated that neither 
pri-let-7a-1 nor other let-7 family members, pri-let-7b, induce the expression of T-MYC.  





expression, A549, and cells that do not express LIN28B, H441, it was concluded that T-
MYC expression is not dependent on pri-let-7a-1 or LIN28B expression.   





 transgenic mouse model by exposing mice to adenovirus-cre 
recombinase, it was hypothesized that T-MYC expression is conserved when cells are 
transduced with virus.  To test this hypothesis, H441 lung adenocarcinoma cells were 
transduced with both lentivirus and adenovirus-cre recombinase and their cell lysates 
were assessed for the expression of T-MYC through SDS-PAGE and immunoblotting.  
As seen in Figure 10, T-MYC expression was not induced by either transduction with 
lentivirus or adenovirus.  This finding indicates that T-MYC expression is not a 
conserved effect seen by the transduction of cells with lentivirus or adenovirus. 
 It was originally hypothesized that the accumulation of unprocessed, primary-let-
7a-1 (pri-let-7a-1) transcripts by LIN28B promoted the expression of a truncated form of 
MYC.  Through this work, it was determined that pri-let-7a-1 does not promote the 
expression of T-MYC and that T-MYC is likely not a protein variant of canonical MYC.  
While this work does not explain why the lentiviral delivery of pri-let-7a-1 increases the 
pro-tumorigenc phenotype in vivo, the elucidation of this effect could reveal additional, 
unknown functions of the microRNA let-7.  These findings could create a paradigm shift 
in the understanding of the functions microRNAs and lead to the creation of effective 










Cell Culture and Transfection 
 A549 and H441 lung adenocarcinoma cell lines were grown in 1X Gibco® RPMI 
1640 supplemented with fetal bovine serum (FBS) and penicillin/streptoMYCin in a cell 
culture incubator maintained at 37°C with 5% CO2.  Passaging and maintenance of cells 
took place in a biological safety cabinet under sterile conditions.  For transfection, A549 
cells were counted by using a hemocytometer and seeded at a volume of 2 mL at 2 x 10
5
 
cells/mL in sterile six well plates on Day 0.  Transfection occurred on Day 1 by 
com ining   μL of Lipofectamine® 2000 transfection reagent  it  1 μg of plasmid and if 
co-transfected, with 25 nM of siRNA in serum and antibiotic free 1X Gibco® RPMI 
1640.  Four hours post transfection, serum free media was aspirated and replaced with 1X 
Gibco® RPMI 1640 supplemented with FBS and penicillin/streptoMYCin.   
Viral Transduction in Cell Culture 
 H441 lung adenocarcinoma cells were counted by using a hemocytometer and 
seeded at a volume of 2 mL at 4 x 10
5
 cells/mL in sterile six well plates on Day 0.  
Tranduction occurred on Day 1 at a multiplicity of infection (MOI) of 2, therefore a total 
concentration of 2 x 10
6
 pfu  ere transduced.  2 μL of 1 x 10
9
 pfu/mL feline 





 it  496 μL of serum and anti iotic free 1X Gi co®  PMI 1640, incu ated at room 
temperature for 5 minutes and added to cells that had 1.5 mL serum and antibiotic free 
1X Gibco® RPMI 1640 media.   00 μL of 4 x 10
6
 pfu/mL adenovirus-cre diluted in 
serum/anti iotic free 1X Gi co®  PMI 1640  as com ined  it  2.4 μL 2M CaCl2, 
incubated for 20 minutes at room temperature, and added to cells that had 1.5 mL serum 
and antibiotic free 1X Gibco® RPMI 1640 media.  One day post transduction, Day 2, the 
media was aspirated and changed to 1X Gibco® RPMI 1640 media supplemented with 
FBS and penicillin/streptoMYCin.   
SDS-PAGE and Immunoblotting 
48 hours post transfection or Day 3 (protocol seen above), cells were lysed with 
1X radioimmunoprecipitation assay (RIPA) buffer supplemented with 1X protease 
inhibitor cocktail with shaking for 10 minutes on ice.  Remaining cellular debris was 
scraped from plates and cell lysates were centrifuged at 13,200 rpm for 10 minutes.  The 
supernatant was moved to a new microcentrifuge tube and lysates were kept at -20°C 
until needed.  A Pierce BCA Protein Assay was then used to determine the concentration 
of protein in each lysate fraction using a bovine serum albumin (BSA) standard curve.  50 
μg of protein,  it  1X Laemli  uffer supplemented  it  2-mercaptoethanol, was then 
boiled at 95°C for 5 minutes.  The protein containing samples were then loaded onto 
Criterion™ TGX™ 12%, 12+2 com  stac ing SDS polyacrylamide gels and run in an 
electrophoretic chamber with 1X Tris-SDS-Glycine running buffer at 150 volts for 1 hour.  
Protein was then transferred to polyvinylidene fluoride (PVDF) membranes activated for 
5 minutes in methanol.  The transfer occurred in a transfer chamber with 1X Glycine-





The PVDF membranes were then blocked in Odyssey® Blocking Buffer (PBS) 
with gentle shaking for 1 hour at room temperature.  Primary MYC antibodies, at a 
concentration of 1:500, were incubated on the PVDF membrane overnight at 4°C with 
gentle shaking.  Membranes were washed three times with phosphate buffer solution 
supplemented with 0.01% Tween-20 (PBST) for 5 minutes with vigorous shaking.  
Secondary antibodies, LI-COR IRDye® 680RD/800RD Goat anti-Mouse or Goat anti-
Rabbit, were diluted in Odyssey® Blocking Buffer (PBS) at a concentration of 1:15,000 
and incubated on the PVDF membranes for 1 hour at room temperature.  Membranes 
were then washed two times with phosphate buffer solution supplemented with 0.01% 
Tween-20 (PBST) for 5 minutes with vigorous shaking followed by one wash with 
phosphate buffer solution (PBS) for 10 minutes with vigorous shaking.  Membranes were 
then imaged on a LI-COR Odyssey® CLx infrared imager.  Primary β-Actin and 
GAPDH antibodies were incubated on PVDF membranes at a concentration of 1:10,000 
for one hour at room temperature, followed by the same protocol above for secondary 
antibodies and imaging. 
RNA Extraction and real-time PCR 
 RNA was extracted and purified from cell lysates post-transfection by direct lysis 
of cells in six  ell plates  it  700 μL of QI zol Lysis  eagent.  Lysis and extraction of 
RNA was then performed using the Qiagen® miRNeasy Mini Kit following the 
manufacturer’s protocol of “Purification of Total     from  nimal Cells”.  T e 
protocol was modified with a DNase digestion, protocol in Appendix B of the miRNeasy 





 Purified RNA was then quantified using a Thermo Scientific  anoDrop™ 2000 
UV-Vis Spectrop otometer.  1 μg of total      as t en reverse transcri ed using a 
miScript® HiFlex buffer in the Qiagen® miScript® II RT kit for 1 hour at 37°C followed 
 y   minutes at 9 °C.  T e 20 μL reverse transcription reaction was then diluted to a total 
volume of 200 μL with nuclease free water and used in real-time polymerase chain 
reaction (qPCR).  qPCR was performed using the Qiagen® miScript® SYBR® Green 
PC  Kit, using 10 μL reaction sizes in  84  ell plates.  Primer sets used are as follows: 
MYC Exon 1/2 primer pair was generated using the NCBI Primer-BLAST program and 
the sequences are as follows: MYC Exon 1/2 Forward:   -
GGGAGGCTATTCTGCCCATT-  and MYC Exon 1/2 Reverse:   -
GAGGCTGCTGGTTTTCCACT-  .  The MYC Exon 2/3 and Actin primer pairs were 
commercially generated Qiagen® Quantitect Primer Assays.  qPCR was performed on an 
 pplied Biosystems  QuantStudio™ 6 Flex  eal-Time PCR system using the following 
thermal cycling conditions; Initial Hold Stage: 95°C for 15 minutes, PCR Stage: 40 
cycles of denature at 95°C for 15 seconds, anneal at 55°C for 30 seconds, and extension 
with fluorescence data capture at 70°C for 30 seconds, and Melt Curve Stage: 95°C for 
15 seconds, 60°C for 1 minute, and 95°C for 15 seconds with fluorescence data capture.  
Ct values obtained from qPCR were analyzed using the comparative Ct method using 
Actin as a gene for normalization of gene expression and the control transfection as the 
internal control for gene expression comparison.   
Cloning 
 Lenti-pri-let-7a-1 plasmids were propagated from pre-existing glycerol stocks in 





(LB) supplemented  it  100 μg/mL of ampicillin  it  vigorous s a ing at  7°C.  
Plasmids were extracted from bacterial cells using a Qiagen® QIAprep® Spin Miniprep 
Kit and quantified using a T ermo Scientific  anoDrop™ 2000 UV-Vis 
Spectrophotometer.   
 Lenti-Δpri-let-7a-1 was created by excising the pri-let-7a-1 sequence from the 
lenti-pri-let-7a-1 plasmid.  This was done by performing a double restriction 
endonuclease digestion of 1 μg of lenti-pri-let-7a-1 with the restriction endonucleases 
  eI and PacI from  e  England Biola s® ( EB®).    20 μL reaction volume  as 
used along  it  0.  μL of each NheI and PacI supplemented with 1X NEB® CutSmart® 
Buffer for 1 hour at 37°C and heat inactivated at 65°C for 20 minutes.    overhangs were 
filled in and   overhangs were removed by using NEB® T4 DNA Polymerase.  The 
reaction was carried out by adding 1 unit of T4 D   polymerase per μg of D  , 
supplemented  it  100 μM d TPs and incu ated on a t ermal cycler for 1  minutes at 
12°C.  The reaction was then run on a 1% agarose gel with a Promega 1kb DNA ladder at 
100 volts for 1 hour.  The gel was visualized on a UVP Benchtop 2 Transilluminator and 
the digested band was extracted from the gel.  The DNA was then extracted from the 
agarose gel using a Qiagen® QI quic ® gel extraction  it.  100 ng of plasmid in a 10 μL 
volume  as t en ligated  it  1 μL of  EB® T  D   ligase and 10 μL of 2X T  D   
ligase buffer and occurred at room temperature overnight.  Ligated plasmids were then 
transformed in NEB® 5-alpha Escherichia coli competent cells.  NEB® 5-alpha cells 
were thawed on ice for 30 minutes, 100 ng of ligated plasmid  as added to  0 μL of 
competent cells and incubated on ice for 30 minutes.  The cells were heat-shocked by 





on ice for 2 minutes.  2 0 μL of SOC media  as added to the cells in a microcentrifuge 
tube and was then incubated at 37°C for 45 minutes with vigorous shaking.  The total 
volume  as t en spread onto LB agar plates supplemented  it  100 μg/mL of ampicillin 
and grown overnight at 37°C.  Multiple colonies were picked and grown in 4 mL 
overnig t cultures in liquid LB supplemented  it  100 μg/mL of ampicillin  it  
vigorous shaking at 37°C.  Plasmids were finally extracted from bacterial cells using a 
Qiagen® QIAprep® Spin Miniprep Kit followed by confirmation restriction 
endonuclease digestion and sequencing of the plasmid at the Purdue low throughput 
sequencing lab.  
 pPNB-1 was created by polymerase chain reaction (PCR) amplification of pri-let-
7a-1 from lenti-pri-let-7a-1 and cloning into pTet-4a, a non-lentiviral plasmid maintained 
in the lab.  pri-let-7a-1 was PCR amplified from lenti-pri-let-7a-1 using the following 
primer pairs generated using NCBI Primer-BLAST: let-7a-1_clon_F:   -
GTACGTACGGCCGCCTCCCCGCCTTAATTA-  and let-7a-1_clon_R:   -
GAGATTTAAATACCTTGCTAGCGGCGCGCCAT-  .  PCR was carried out by using 
NEB® Q5® High Fidelity DNA Polymerase using the following conditions for each 
reaction:   μL  X Q   eaction Buffer, 0.  μL of 100 μM d TPs, 1.2  μL of 10 μM 
forward and reverse primer, 10 ng of lenti-pri-let-7a-1 plasmid D  , 0.2  μL Q ® D   
Polymerase and 1 .7  μL nuclease free  ater.  T e PC  t ermal cycling conditions used 
are as follows: initial denaturation at 98°C for 30 seconds, 30 cycles of: denature at 98°C 
for 10 seconds, anneal at 60°C for 30 seconds and extension at 72°C for 1.5 minutes, 
followed by a final extension at 72°C for 5 minutes and hold at 4°C.  Reactions were then 





Bands were extracted from the gel and DNA was extracted from the agarose gel using a 
Qiagen® QIAquick® gel extraction kit.  The PCR amplified product and pTet-4a were 
t en digested to create compati le ends for ligation.  1 μg of eac   ere first digested  it  
SwaI supplemented with with NEB® Buffer 3.1.  The reaction components for digestion 
of t e PC  product are as follo s: 1 μL S aI,  0 μL PC  product,   μL  EBuffer  .1 
and 14 μL of deionized  ater.  T e reaction components for digestion of t e pTet-4a are 
as follo s: 4.  μL D  , 2 μL  EBuffer  .1, 0.  μL S aI and 1 .2  μL of deionized 
water.  Both reactions were incubated at 25°C for 1 hour followed by inactivation at 65°C 
for 20 minutes.  1 μL of BsiWi  as t en added to eac  reaction and incu ated at   °C for 
one hour.  Digested pTet-4a was run on a 1% agarose gel with the Promega 1kb ladder 
and its DNA was extracted from the agarose gel using the Qiagen® QIAquick® gel 
extraction kit.  The digested PCR insert was purified using the Qiagen® QIAquick® 
Purification kit.  The digested pTet-4a vector was ligated to the digested pri-let-7a-1 
insert at a molar ratio of 1:3 by using NEB® T3 DNA ligase.  The reaction was 
performed as follo s: 1 μL digested pTet-4a, 6 μL digested pri-let-7a-1 DNA insert, 10 
μL  EB® T  D   ligase  uffer and 1 μL  EB® T  D   ligase.  The reaction was left 
at room temperature overnight.  Ligated plasmids were then transformed in NEB® 5-
alpha Escherichia coli competent cells.  NEB® 5-alpha cells were thawed on ice for 30 
minutes, 100 ng of ligated plasmid  as added to  0 μL of competent cells and incubated 
on ice for 30 minutes.  The cells were heat-shocked by placing the tube in a 42°C water 
 at  for 4  seconds follo ed immediately  y incu ation on ice for 2 minutes.  2 0 μL of 
SOC media was added to the cells in a microcentrifuge tube and was then incubated at 





agar plates supplemented  it  100 μg/mL of ampicillin and gro n overnig t at  7°C.  
Multiple colonies were picked and grown in 4 mL overnight cultures in liquid LB 
supplemented  it  100 μg/mL of ampicillin  it  vigorous s a ing at  7°C.  Plasmids 
were finally extracted from bacterial cells using a Qiagen® QIAprep® Spin Miniprep Kit 
followed by confirmation restriction endonuclease digestion and sequencing of the 
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